Tokyo Tape
Sign in
← Chiome Bioscience

Annual report

4583.TEDINET S100XUJT
Period2025-01-01 → 2025-12-31
Filed2026-03-27
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 76
MetricValuePeriodScopeSource row
Revenue¥593m2025-01-01 → 2025-12-31StandaloneNet sales
Revenue¥781m2024-01-01 → 2024-12-31StandaloneNet sales
Revenue¥682m2023-01-01 → 2023-12-31vStandaloneNet sales (5-year summary)
Revenue¥631m2022-01-01 → 2022-12-31vStandaloneNet sales (5-year summary)
Revenue¥713m2021-01-01 → 2021-12-31dStandaloneNet sales (5-year summary)
Operating income−¥980m2025-01-01 → 2025-12-31StandaloneOperating income
Operating income−¥1.0bn2024-01-01 → 2024-12-31StandaloneOperating income
Ordinary income−¥989m2025-01-01 → 2025-12-31StandaloneOrdinary income
Ordinary income−¥1.0bn2024-01-01 → 2024-12-31StandaloneOrdinary income
Ordinary income−¥1.2bn2023-01-01 → 2023-12-31vStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥1.2bn2022-01-01 → 2022-12-31vStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥1.3bn2021-01-01 → 2021-12-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥980m2025-01-01 → 2025-12-31StandaloneIncome before income taxes
Profit before tax−¥1.0bn2024-01-01 → 2024-12-31StandaloneIncome before income taxes
Net income−¥983m2025-01-01 → 2025-12-31StandaloneProfit loss
Net income−¥1.0bn2024-01-01 → 2024-12-31StandaloneProfit loss
Net income−¥1.2bn2023-01-01 → 2023-12-31vStandaloneNet income loss (5-year summary)
Net income−¥1.2bn2022-01-01 → 2022-12-31vStandaloneNet income loss (5-year summary)
Net income−¥1.5bn2021-01-01 → 2021-12-31dStandaloneNet income loss (5-year summary)
Total assets¥1.7bnat 2025-12-31StandaloneAssets
Total assets¥2.5bnat 2024-12-31StandaloneAssets
Total assets¥1.8bnat 2023-12-31vStandaloneTotal assets (5-year summary)
Total assets¥2.2bnat 2022-12-31vStandaloneTotal assets (5-year summary)
Total assets¥2.3bnat 2021-12-31dStandaloneTotal assets (5-year summary)
Total liabilities¥605mat 2025-12-31StandaloneLiabilities
Total liabilities¥549mat 2024-12-31StandaloneLiabilities
Net assets / equity¥1.1bnat 2025-12-31StandaloneNet assets
Net assets / equity¥1.9bnat 2024-12-31StandaloneNet assets
Net assets / equity¥1.2bnat 2023-12-31vStandaloneNet assets
Net assets / equity¥1.8bnat 2022-12-31vStandaloneNet assets (5-year summary)
Net assets / equity¥1.9bnat 2021-12-31dStandaloneNet assets (5-year summary)
Cash and deposits¥1.2bnat 2025-12-31StandaloneCash and deposits
Cash and deposits¥2.1bnat 2024-12-31StandaloneCash and deposits
Cash & equivalents¥1.2bnat 2025-12-31StandaloneCash and cash equivalents
Cash & equivalents¥2.1bnat 2024-12-31StandaloneCash and cash equivalents
Cash & equivalents¥1.3bnat 2023-12-31vStandaloneCash and cash equivalents
Cash & equivalents¥1.7bnat 2022-12-31vStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥1.8bnat 2021-12-31dStandaloneCash and cash equivalents (5-year summary)
Operating cash flow−¥936m2025-01-01 → 2025-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.0bn2024-01-01 → 2024-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.1bn2023-01-01 → 2023-12-31vStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥1.2bn2022-01-01 → 2022-12-31vStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥1.1bn2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow−¥55m2025-01-01 → 2025-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow¥173,0002023-01-01 → 2023-12-31vStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥35m2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow¥133m2025-01-01 → 2025-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥1.7bn2024-01-01 → 2024-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥667m2023-01-01 → 2023-12-31vStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥1.1bn2022-01-01 → 2022-12-31vStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥271m2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥-14.472025-01-01 → 2025-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-17.542024-01-01 → 2024-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-24.622023-01-01 → 2023-12-31vStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-28.262022-01-01 → 2022-12-31vStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-36.742021-01-01 → 2021-12-31dStandaloneBasic earnings loss per share (5-year summary)
Net assets per share¥16.18at 2025-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥28.53at 2024-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥21.66at 2023-12-31vStandaloneNet assets per share (5-year summary)
Net assets per share¥36.7at 2022-12-31vStandaloneNet assets per share (5-year summary)
Net assets per share¥45.55at 2021-12-31dStandaloneNet assets per share (5-year summary)
Equity ratio64.1%at 2025-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio77.4%at 2024-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio65.1%at 2023-12-31vStandaloneEquity to asset ratio (5-year summary)
Equity ratio80.2%at 2022-12-31vStandaloneEquity to asset ratio (5-year summary)
Equity ratio79.4%at 2021-12-31dStandaloneEquity to asset ratio (5-year summary)
Shares issued68,453,800at 2025-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued66,969,000at 2024-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued52,640,200at 2023-12-31vStandaloneTotal number of issued shares (5-year summary)
Shares issued48,423,500at 2022-12-31vStandaloneTotal number of issued shares (5-year summary)
Shares issued40,781,500at 2021-12-31dStandaloneTotal number of issued shares (5-year summary)
Employees49at 2025-12-31StandaloneNumber of employees
Employees47at 2024-12-31StandaloneNumber of employees
Employees51at 2023-12-31vStandaloneNumber of employees
Employees49at 2022-12-31vStandaloneNumber of employees
Employees49at 2021-12-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 22
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment profit2025-01-01 → 2025-12-31−¥559m
Drug Discovery And Developmentreportable segmentsegment profit2025-01-01 → 2025-12-31−¥777m
Drug Discovery Supportreportable segmentdepreciation2025-01-01 → 2025-12-31¥4m
Drug Discovery Supportreportable segmentrevenue2025-01-01 → 2025-12-31¥593m
Drug Discovery Supportreportable segmentrevenue external2025-01-01 → 2025-12-31¥593m
Drug Discovery Supportreportable segmentsegment profit2025-01-01 → 2025-12-31¥356m
—segment totalemployeesat 2025-12-3139 pure
Total Of Reportable Segments And Otherssegment totaldepreciation2025-01-01 → 2025-12-31¥4m
Total Of Reportable Segments And Otherssegment totalrevenue2025-01-01 → 2025-12-31¥593m
Total Of Reportable Segments And Otherssegment totalrevenue external2025-01-01 → 2025-12-31¥593m
Total Of Reportable Segments And Otherssegment totalsegment profit2025-01-01 → 2025-12-31−¥421m
Reconciling Itemsreconcilingdepreciation2024-01-01 → 2024-12-31¥1m
Reconciling Itemsreconcilingsegment profit2024-01-01 → 2024-12-31−¥527m
Drug Discovery And Developmentreportable segmentrevenue2024-01-01 → 2024-12-31¥203m
Drug Discovery And Developmentreportable segmentrevenue external2024-01-01 → 2024-12-31¥203m
Drug Discovery And Developmentreportable segmentsegment profit2024-01-01 → 2024-12-31−¥814m
Drug Discovery Supportreportable segmentrevenue2024-01-01 → 2024-12-31¥578m
Drug Discovery Supportreportable segmentrevenue external2024-01-01 → 2024-12-31¥578m
Drug Discovery Supportreportable segmentsegment profit2024-01-01 → 2024-12-31¥310m
Total Of Reportable Segments And Otherssegment totalrevenue2024-01-01 → 2024-12-31¥781m
Total Of Reportable Segments And Otherssegment totalrevenue external2024-01-01 → 2024-12-31¥781m
Total Of Reportable Segments And Otherssegment totalsegment profit2024-01-01 → 2024-12-31−¥504m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 832
ItemContextValueUnit
Subsidy income ope cfPrior1YearDuration_NonConsolidatedMember-28011000JPY
Subsidy income ope cfCurrentYearDuration_NonConsolidatedMember－JPY
Decrease increase in notes and accounts receivable trade ope cfPrior1YearDuration_NonConsolidatedMember32130000JPY
Decrease increase in notes and accounts receivable trade ope cfCurrentYearDuration_NonConsolidatedMember-20933000JPY
Decrease increase in inventories ope cfPrior1YearDuration_NonConsolidatedMember17936000JPY
Decrease increase in inventories ope cfCurrentYearDuration_NonConsolidatedMember-3241000JPY
Decrease increase in advance payments ope cfPrior1YearDuration_NonConsolidatedMember-15195000JPY
Decrease increase in advance payments ope cfCurrentYearDuration_NonConsolidatedMember-33022000JPY
Decrease increase in consumption taxes refund receivable ope cfPrior1YearDuration_NonConsolidatedMember-2179000JPY
Decrease increase in consumption taxes refund receivable ope cfCurrentYearDuration_NonConsolidatedMember-5095000JPY
Increase decrease in notes and accounts payable trade ope cfPrior1YearDuration_NonConsolidatedMember-10538000JPY
Increase decrease in notes and accounts payable trade ope cfCurrentYearDuration_NonConsolidatedMember10245000JPY
Increase decrease in contract liabilities ope cfPrior1YearDuration_NonConsolidatedMember－JPY
Increase decrease in contract liabilities ope cfCurrentYearDuration_NonConsolidatedMember130329000JPY
Increase decrease in accounts payable other ope cfPrior1YearDuration_NonConsolidatedMember20763000JPY
Increase decrease in accounts payable other ope cfCurrentYearDuration_NonConsolidatedMember-55585000JPY
Increase decrease in accrued expenses ope cfPrior1YearDuration_NonConsolidatedMember3969000JPY
Increase decrease in accrued expenses ope cfCurrentYearDuration_NonConsolidatedMember-15002000JPY
Other net ope cfPrior1YearDuration_NonConsolidatedMember4488000JPY
Other net ope cfCurrentYearDuration_NonConsolidatedMember36397000JPY
Subtotal ope cfPrior1YearDuration_NonConsolidatedMember-993005000JPY
Subtotal ope cfCurrentYearDuration_NonConsolidatedMember-931707000JPY
Interest income received ope cfPrior1YearDuration_NonConsolidatedMember182000JPY
Interest income received ope cfCurrentYearDuration_NonConsolidatedMember2458000JPY
Interest expenses paid ope cf fin cfPrior1YearDuration_NonConsolidatedMember-2865000JPY
Interest expenses paid ope cf fin cfCurrentYearDuration_NonConsolidatedMember-3155000JPY
Income taxes paid ope cfPrior1YearDuration_NonConsolidatedMember-5010000JPY
Income taxes paid ope cfCurrentYearDuration_NonConsolidatedMember-3616000JPY
Income taxes refund ope cfPrior1YearDuration_NonConsolidatedMember2000JPY
Income taxes refund ope cfCurrentYearDuration_NonConsolidatedMember32000JPY
Net cash provided by used in operating activitiesPrior1YearDuration_NonConsolidatedMember-1000695000JPY
Net cash provided by used in operating activitiesCurrentYearDuration_NonConsolidatedMember-935988000JPY
Purchase of property plant and equipment inv cfPrior1YearDuration_NonConsolidatedMember－JPY
Purchase of property plant and equipment inv cfCurrentYearDuration_NonConsolidatedMember-40080000JPY
Payments for lease and guarantee deposits inv cfPrior1YearDuration_NonConsolidatedMember－JPY
Payments for lease and guarantee deposits inv cfCurrentYearDuration_NonConsolidatedMember-15383000JPY
Net cash provided by used in investment activitiesPrior1YearDuration_NonConsolidatedMember－JPY
Net cash provided by used in investment activitiesCurrentYearDuration_NonConsolidatedMember-55463000JPY
Increase decrease in short term loans payable fin cfPrior1YearDuration_NonConsolidatedMember-9500000JPY
Increase decrease in short term loans payable fin cfCurrentYearDuration_NonConsolidatedMember-194800000JPY
Proceeds from issuance of bonds fin cfPrior1YearDuration_NonConsolidatedMember250000000JPY
Proceeds from issuance of bonds fin cfCurrentYearDuration_NonConsolidatedMember200000000JPY
Redemption of bonds fin cfPrior1YearDuration_NonConsolidatedMember-250000000JPY
Redemption of bonds fin cfCurrentYearDuration_NonConsolidatedMember-25000000JPY
Proceeds from issuance of common stock fin cfPrior1YearDuration_NonConsolidatedMember1749912000JPY
Proceeds from issuance of common stock fin cfCurrentYearDuration_NonConsolidatedMember145055000JPY
Proceeds from issuance of subscription rights to shares fin cfPrior1YearDuration_NonConsolidatedMember－JPY
Proceeds from issuance of subscription rights to shares fin cfCurrentYearDuration_NonConsolidatedMember14971000JPY
Payments for issuance of subscription rights to shares fin cfPrior1YearDuration_NonConsolidatedMember-582000JPY
Payments for issuance of subscription rights to shares fin cfCurrentYearDuration_NonConsolidatedMember-7027000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 13 of 13 passed
balance sheet identitynon_consolidated 2024-12-31pass rounding
balance sheet identitynon_consolidated 2025-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2023-12-31pass
statement vs summary · net assetsnon_consolidated 2024-12-31pass
statement vs summary · net assetsnon_consolidated 2025-12-31pass
statement vs summary · operating cash flownon_consolidated 2024-01-01/2024-12-31pass
statement vs summary · operating cash flownon_consolidated 2025-01-01/2025-12-31pass
statement vs summary · revenuenon_consolidated 2024-01-01/2024-12-31pass
statement vs summary · revenuenon_consolidated 2025-01-01/2025-12-31pass
statement vs summary · total assetsnon_consolidated 2024-12-31pass
statement vs summary · total assetsnon_consolidated 2025-12-31pass